Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Prostatic Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hodgkin Disease 1Down Syndrome 1

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × prednylidene × Clear all
NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡